Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
Microbes and Infection|April 7, 2007
Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccineW Ripley BallouExpert Review of Vaccines|March 8, 2008
Plasmodium falciparum malaria vaccines in developmentJohan Vekemans, W Ripley BallouMalaria Journal|January 1, 2010
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available dataVasee S Moorthy, W Ripley BallouThe American Journal of Tropical Medicine and Hygiene|January 31, 2008
Two decades of commitment to malaria vaccine development: GlaxoSmithKline BiologicalsW Ripley Ballou, Conor P CahillThe Journal of Infectious Diseases|February 25, 2003
Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1W Ripley Ballou, Jennifer L Reed, William Noble, et al.Antimicrobial Agents and Chemotherapy|February 13, 2008
Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malariaMark E Polhemus, Shon Remich, Bernhards Ogutu, et al.Human Vaccines & Immunotherapeutics|November 27, 2014
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adultsGeert Leroux-Roels, Isabel Leroux-Roels, Frédéric Clement, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2003
Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gammaPeifang Sun, Robert Schwenk, Katherine White, et al.Human Vaccines|March 12, 2009
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The GambiaKalifa Bojang, Paul Milligan, Margaret Pinder, et al.Pageof 8